"Completely disappointed"! Deutsche Bank downgrades Novo Nordisk rating for the first time
```
Novo Nordisk encountered setbacks in key clinical trials for its weight loss drug, triggering a rare wave of downgrades by Wall Street investment banks, with Deutsche Bank lowering its stock rating for the first time in five years.
According to data released by Novo Nordisk on Monday, its weight loss